Retinol deuterated

Drug Profile

Retinol deuterated

Alternative Names: ALK-001; C20-D3-vitamin A; Deuterated-retinol; Deuterated-vitamin-A; Vitamin-A-deuterated

Latest Information Update: 01 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Columbia University
  • Developer Alkeus Pharmaceuticals
  • Class Eye disorder therapies; Retinoids; Vitamins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Stargardt disease
  • Phase I Age-related macular degeneration; Retinal dystrophies

Most Recent Events

  • 01 Aug 2015 Phase-II clinical trials in Stargardt disease 1 in USA (PO) (NCT02402660)
  • 10 Apr 2015 Alkeus Pharmaceuticals plans the phase I TEASE trial in Stargardt disease in USA (NCT02402660)
  • 01 Feb 2015 Alkeus Pharmaceuticals completes a phase I trial in Stargardt disease 1, Age-related macular degeneration and Retinal dystrophies (In volunteers) in USA (NCT02230228)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top